Medtronic CEO Geoffrey Martha sells $4.75M in stock after guidance raise

Geoffrey Martha sold 50,000 shares of Medtronic on October 16, 2026, reducing his personal stake by roughly 18%. The sale came shortly after the company raised its fiscal 2027 guidance, a moment when most executives would be inclined to hold rather than cash out.

The filing disclosed no 10b5-1 plan, so the sale was discretionary rather than pre-scheduled under a rules-based program. Investor attention follows that status closely when the seller is the chief executive.

A 10b5-1 plan lets an executive set a selling schedule in advance, before they possess any material non-public information, so future sales happen automatically regardless of what the company announces. Without that structure on file, the timing of Martha's decision to sell was entirely at his discretion.

That does not make the sale improper, and insider selling has many legitimate explanations including diversification, taxes, and personal financial planning. But an 18% reduction in holdings by a sitting CEO, executed without a pre-disclosed plan and immediately after a positive guidance update, is the kind of signal that institutional investors and retail traders alike tend to flag and monitor closely.